NASDAQ$PGNY
Progyny Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Progyny had a solid first quarter with record revenue, reflecting strong utilization and expansion of client base and covered lives. Profitability and margins expanded due to operational efficiencies and favorable comparisons to the prior year period.
Progyny reported a record first quarter revenue of $122.1 million, a 51% increase compared to the first quarter of 2020. Net income increased by 318% to $15.2 million, or $0.15 income per diluted share. The company issued revenue guidance of $126.0 to $131.0 million for the second quarter of 2021, reflecting growth of 95% to 103%.
- Revenue was $122.1 million, a 51% increase compared to Q1 2020.
- Fertility benefit services revenue was $88.9 million, a 50% increase from Q1 2020.
- Pharmacy benefit services revenue was $33.3 million, a 54% increase compared to Q1 2020.
- Net income was $15.2 million, an increase of 318% from Q1 2020.
Headline financials
Revenue & EPS history
Progyny · Revenue · Quarterly
$122M
Revenue by segment
Progyny · $122M total across 2 segments · Q1 2021
- Fertility Benefit Services$88.9M+49.7%72.7%
- Pharmacy Benefit Services$33.3M+54.2%27.3%
Forward guidance
The company is providing the following financial guidance for the second quarter of 2021: Revenue is projected to be $126.0 million to $131.0 million, reflecting growth of 95% to 103%. Net income is projected to be $6.5 million to $8.8 million, or $0.06 to $0.09 per diluted share. Adjusted EBITDA is projected to be $17.5 million to $19.0 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-1.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
38%
11 / 29 earnings
Positive
+26.4%
Q2 2022
Best reaction
-20.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +25.4% | +38.2% | |
| Q4 2025 | -20.5% | -20.0% | -22.4% | |
| Q3 2025 | +24.3% | +33.6% | +33.4% | |
| Q1 2025 | -9.7% | -6.5% | -7.2% | |
| Q4 2024 | -1.5% | -5.2% | -4.3% | |
| Q3 2024 | -18.5% | -19.3% | -12.9% | |
| Q2 2024 | -17.7% | -14.7% | -6.4% | |
| Q1 2024 | -14.4% | -14.6% | -14.2% | |
| Q4 2023 | -13.1% | -9.7% | -4.3% | |
| Q3 2023 | -4.3% | -2.1% | +17.8% | |
| Q2 2023 | +4.9% | -2.8% | -8.6% | |
| Q1 2023 | +9.3% | +5.9% | +16.8% | |
| Q4 2022 | +22.9% | +18.4% | +7.7% | |
| Q3 2022 | -2.6% | +2.0% | -13.8% | |
| Q2 2022 | +26.4% | +25.5% | +15.4% | |
| Q1 2022 | -7.1% | -15.6% | -23.1% | |
| Q4 2021 | +11.5% | +13.0% | +31.6% | |
| Q3 2021 | +2.5% | +5.8% | -22.2% | |
| Q2 2021 | -12.8% | -17.1% | +4.3% | |
| Q1 2021 | -3.2% | -8.7% | +18.4% | |
| Q4 2020 | -15.5% | -14.9% | -14.4% | |
| Q3 2020 | -0.3% | +7.0% | +38.7% | |
| Q2 2020 | +0.4% | +8.4% | -0.9% | |
| Q1 2019 | -2.4% | +4.8% | -13.7% | |
| Q1 2020 | +21.8% | +18.8% | +2.1% | |
| Q4 2017 | -3.7% | -6.3% | -8.3% | |
| Q4 2019 | -12.2% | -15.5% | -39.0% | |
| Q4 2018 | -0.2% | -5.0% | -7.0% | |
| Q3 2019 | +0.5% | +0.3% | -6.5% | |
| Q2 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro